- Laboratorieleverantörernas branschförening
Abstracts 22nd of October 2014
Nordic Biolabs AB
Which gloves will protect you in different applications?
How do you avoid skin problems related to using gloves?
This lecture is for those who want to know which glove to choose for different applications. We will also talk
about different skin problems that can occur when using gloves, why they occur and how to avoid them.
In addition to this you will learn about requirements and how to interpret markings and symbols on the boxes
of gloves.
Charlotte Otéma, Nick Gardner, Nordic Biolabs
VWR International
"VWR Safety seminary - Examine and evaluate chemical risks in the working environment”
Scope: The purpose of examining the risks is to determine what actions are needed for the work to be done
safely. Begin with a general investigation and risk assessment. Determine how the business should be divided
into areas that can be assesses individually. Do the following three steps:
Step1: Find out what risks that exist, their dangerous properties and the frequency.
Step 2. Identify dangerous situations
Step 3. Decide what actions are needed
The safety seminar will cover all 3 steps and also include an orientation about safety data sheets; structure,
important areas etc.
Magnus Rignell & Hege Richter Jonsen, VWR International
Roche Diagnostics
"Translational Research and Personalized Health Care”
Personalized Health Care, PHC, is a central part of Roches global research and development strategy, and a key
component in our daily activities both in our Pharma and our Diagnostics divisions. In this lecture, we would
like to present how our two pillars of Pharma and Diagnostics are working together across the entire value
chain, from bench to bedside, to enable personalized healthcare for patients today and in the future."
Ingvar Rydén, Md., Roche
Swedish Labtech
Klara Norra Kyrkogata 31
Box 22307
104 22 Stockholm
Tel. 08-508 938 00
Fax 08-508 938 01
Webb:
E-post:
www.swedishlabtech.se
swedishlabtech@branschkansliet.se
- Laboratorieleverantörernas branschförening
TATAA Biocenter
High throughput single cell and subcellular expression profiling
Introduction
Biological samples are composed of large number of cells of different types. When studying traditional samples
containing many cells only the collective response of all the cells present is measured. However, the cells may
respond differently and a small subpopulation may be critical. Today, these systems can be studied using single
cell expression profiling. Here we apply single cell profiling to study the response of astrocytes to brain trauma
using mouse model. We also study asymmetric cell division during early development of Xenopus laevis by
single cell and intracellular profiling using qPCR tomography.
Material and Methods
Single astrocytes from mice were enriched and collected by FACS using GFP under the control of the GFAP
promoter as marker. Cells were lysed (Cellulyser, TATAA Biocenter), reverse transcribed (GrandScript, TATAA
Biocenter), pre-amplified (GrandMaster PreAmp, TATAA Biocenter), and profiled using high throughput
microfluidic qPCR (BioMark, Fluidigm). Data were pre-processed and cells were classified using multivariate
methods (PCA, SOM, clustering) and correlation analysis with the GenEx software (ver. 6, MultiD Analysis).
Results and Discussion
Astrocytes were collected from mouse brains at different time points after the induction of focal ischemia. Each
cell was profiled for the expression of 47 genes. Classification revealed astrocyte reactivation with the
formation of distinct subtypes (Figure). Single cell and subcellular blastomere profiling revealed asymmetric cell
division is induced by asymmetric distribution of key cell fate determinants already in the fertilized cell.
Conclusions
Single cell profiling is most powerful to study complex biological samples, revealing heterogeneity and to
identify key expression pathways active in critical cell types. Power and robust flows for experimental and
analytical analysis are available, as well as highly optimized reagents.
Mikael Kubista, CEO, TATAA Biocenter
Qiagen
Next Generation Sequencing (NGS)
Next Generation Sequencing (NGS) applications are rapidly developing for routine clinical use. Until recently
whole genome sequencing and/or exome sequencing were rarely used when certain (undiagnosed) genetic
diseases were suspected. The sequencing and analysis were performed by highly specialized research
laboratories or core facilities with access expensive equipment and skilled bioinformaticians. During the last 1-2
years smaller and cheaper NGS instrumentation have been developed as well as more simplified preparative
and analytical workflows. This development allows for moving NGS technologies and applications into clinical
laboratories, which will have a transformational impact on healthcare and diagnostics.
However, QIAGEN sees that current offerings for NGS workflows do not meet the demands of the clinical
environment. The company has therefore during the last year developed and launched numerous NGS
products and acquired several companies with accompanying products with the aim to become market leader
of products for clinical NGS applications. The general theme of our product development is “Sample to Insight”
where we provide streamlined workflow solutions from sample extraction, over target enrichment, library
production, to biological and clinical interpretation of the sequencing data. We can now provide such processes
for the sequencing platforms presently on the market and with the coming GeneReader™ system QIAGEN can
fully integrate and automate the complete NGS workflow from Sample to Insight.
Swedish Labtech
Klara Norra Kyrkogata 31
Box 22307
104 22 Stockholm
Tel. 08-508 938 00
Fax 08-508 938 01
Webb:
E-post:
www.swedishlabtech.se
swedishlabtech@branschkansliet.se
- Laboratorieleverantörernas branschförening
In the talk we will describe how the QIAGEN solutions will allow for the movement of NGS practical workflows
as well as analyses and data interpretation from the dedicated core facilities to routine clinical laboratories.
Erik Söderbäck, Qiagen
BergmanLabora
How fit is your fat?
There has been continuous increase of interest in the constituents of food and beverages for the last decade.
Both from the regulatory bodies as well as from the consumers. What is good for us? What is not? What is
dangerous and should be avoided? And what should be banned outright?
We present three analytical scenarios to investigate the total content of fat in meat which is used as raw
material for production for example sausages and hamburgers. This is done by saponification of fat,
methylation of fatty acids to FAMEs with consequent analysis by GC/FID. The method allows at the same time
to “fingerprint” separate fatty acids and to discriminate between “good and bad” (cis- and trans-) fatty acids.
Another, quick method that can determine total fat in the raw material directly in the production hall – NIR or
Near Infrared Spectroscopy – is presented here.
We are moving towards total ban of the use of steroids for treatment of animals. A method of control of
meat/fat product, which can detect very small amounts of steroids, is UHPLC with MSMS detection is
discussed.
Ilya Zelikman, PhD
__________________________________________________________________________________
Sigma-Aldrich Sweden AB
Crispr abstract
"The discovery of the type II prokaryotic CRISPR/Cas immune system has allowed for the development of an
RNA guided genome editing tool that is simple, easy and quick to implement. Sigma Aldrich have developed a
single vector system with a Cas9-GFP and a U6-guideRNA expression cassette for CRISPR/Cas9 delivery and
expression.CRISPR/Cas systems along with our CompoZR ZFN technology provide a quick and affordable
solution to targeted genome editing in a wide variety of species and cell types. In this presentation we will
discuss how both technologies can be utilised to generate precisely targeted genome edits."
Peter Lindqvist, Sigma Aldrich
___________________________________________________________________________
Swedish Labtech
Klara Norra Kyrkogata 31
Box 22307
104 22 Stockholm
Tel. 08-508 938 00
Fax 08-508 938 01
Webb:
E-post:
www.swedishlabtech.se
swedishlabtech@branschkansliet.se